Allakos Inc. (Nasdaq: ALLK) today announced positive results from its Phase 2 randomized, double-blind, placebo-controlled trial of AK002 in patients ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Hot FDA News

Allakos (ALLK) Trades at High, Up 125%August 5, 2019 9:53 AM Allakos Announces AK002 Met All Prespecified Primary and Secondary Endpoints in Phase 2 Randomized, Double-Blind, Placebo-Controlled Study in Patients with Eosinophilic Gastritis (EG) and/or EosinophiAugust 5, 2019 7:00 AM